Outcome of Board meeting is hereby submitted
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.8 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
HOCL's Board, on 13th November 2025, approved unaudited standalone and consolidated financial results for Q2 and H1 FY26 (ended 30 Sept 2025) with an unmodified auditor opinion from M/s Balan & Co. Standalone Q2 revenue from operations fell sharply to Rs. 126.27 crore from Rs. 174.72 crore in Q2 FY25 (down ~28%), and the company reported a standalone net loss of Rs. 18.14 crore for the quarter and Rs. 24.64 crore for the half-year, versus a profit of Rs. 39.15 crore for FY25 (boosted by a one-time GOI loan waiver). The auditor flagged emphasis-of-matter notes on the going-concern assumption (restructuring plan in progress, land sales at Rasayani and Panvel), the subsidiary Hindustan Fluorocarbons loan, and non-compliance with SEBI LODR norms on independent directors. Operating cash flow for H1 was negative at Rs. (22.06) crore. The Board also noted CAG's re-appointment of statutory auditors for FY26 and the appointment of Shri Sangram Kumar Mishra as the new Chairman & Managing Director.
Continued quarterly losses and declining revenue are negative for shareholders, though the going-concern status is preserved as the Kochi Phenol plant is operational. The unresolved SEBI LODR non-compliance on independent directors remains a regulatory overhang, while the new CMD appointment brings the Board back to minimum strength.